Effect of haemodialysis on the pharmacokinetics of cetirizine
- Cite this article as:
- Awni, W.M., Yeh, J., Halstenson, C.E. et al. Eur J Clin Pharmacol (1990) 38: 67. doi:10.1007/BF00314806
The pharmacokinetics of Cetirizine, a histamine H1-receptor antagonist, were investigated in five renal failure patients undergoing chronic haemodialysis therapy. The patients received one 10 mg cetirizine dihydrochloride capsule 3 h before haemodialysis.
Concentrations of cetirizine in serum and dialysate were determined by HPLC. The maximum serum cetirizine concentration and the time to reach that maximum were 285 μg·1−1 and 2.0 h, respectively. The terminal disposition half-life of cetirizine in these patients was 19.3 h.
The haemodialysis clearance of cetirizine was 14.0 ml · min−1. Although this is approximately 33% of the apparent total body clearance of cetirizine in subjects with normal renal function, the fraction of the dose removed by dialysis was only 9.4%. Thus, since haemodialysis does not produce a clinically significantly alteration in cetirizine elimination, no supplemental dose should be necessary after dialysis.
Key wordsCetirizine haemodialysis pharmacokinetics renal failure
Unable to display preview. Download preview PDF.